| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
208.71(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $22.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
53,265 |
53,265 |
74,223 |
229,905 |
| Total Sell Value |
$339,844 |
$339,844 |
$555,147 |
$3,944,931 |
| Total People Sold |
3 |
3 |
4 |
13 |
| Total Sell Transactions |
3 |
3 |
5 |
43 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
18,718 |
70,077 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
55,813 |
278,751 |
|
- |
|
| Dolmetsch Ricardo |
President, R&D |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
12,729 |
77,729 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
18,573 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2021-02-15 |
4 |
AS |
$34.88 |
$134,452 |
D/D |
(3,800) |
222,938 |
|
-15% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2021-01-29 |
4 |
AS |
$35.49 |
$249,049 |
D/D |
(7,000) |
226,738 |
|
4% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2021-01-28 |
4 |
S |
$35.96 |
$567,901 |
D/D |
(15,750) |
233,738 |
|
-2% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2021-01-27 |
4 |
S |
$36.59 |
$585,885 |
D/D |
(15,749) |
249,488 |
|
-2% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2021-01-27 |
4 |
S |
$37.38 |
$278,369 |
D/D |
(7,447) |
48,619 |
|
-2% |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2021-01-27 |
4 |
S |
$37.23 |
$178,257 |
D/D |
(4,788) |
51,359 |
|
-2% |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2021-01-26 |
4 |
S |
$39.00 |
$37,128 |
D/D |
(952) |
56,066 |
|
3% |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2021-01-26 |
4 |
S |
$39.01 |
$27,814 |
D/D |
(713) |
56,147 |
|
3% |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2021-01-26 |
4 |
S |
$39.09 |
$23,610 |
D/D |
(604) |
40,919 |
|
3% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-12-16 |
4 |
AS |
$48.34 |
$605,173 |
D/D |
(12,501) |
265,237 |
|
-30% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-12-16 |
4 |
OE |
$7.53 |
$94,133 |
D/D |
12,501 |
277,738 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-11-19 |
4 |
AS |
$45.18 |
$513,019 |
D/D |
(11,355) |
265,237 |
|
-26% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-11-19 |
4 |
OE |
$7.53 |
$23,531 |
D/D |
3,125 |
276,592 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-11-18 |
4 |
AS |
$43.11 |
$450,579 |
D/D |
(10,313) |
273,467 |
|
-21% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-11-18 |
4 |
OE |
$7.53 |
$24,216 |
D/D |
3,216 |
283,780 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-10-14 |
4 |
AS |
$35.82 |
$188,256 |
D/D |
(5,250) |
280,564 |
|
6% |
|
| Gut Robert |
Chief Medical Officer |
• • – |
2020-09-21 |
4 |
S |
$39.12 |
$170,250 |
D/D |
(4,352) |
41,523 |
|
6% |
|
| Kuta Alexander Edward Iii |
Executive VP, Operations |
• – – |
2020-09-18 |
4 |
S |
$41.18 |
$91,831 |
D/D |
(2,230) |
56,860 |
|
14% |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-09-16 |
4 |
AS |
$40.36 |
$304,939 |
D/D |
(7,500) |
285,814 |
|
-15% |
|
| Dolmetsch Ricardo |
President |
• – – |
2020-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
65,000 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2020-08-25 |
4 |
AS |
$40.27 |
$12,081 |
D/D |
(300) |
293,314 |
|
5% |
|
336 Records found
|
|
Page 7 of 14 |
|
|
0.01 (0.21%) 
